association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis

Purpose: Although several studies have suggested an association between thymidylate synthase (TS) expression and outcomes of gastric cancer (GC) patients treated with fluoropyrimidine-based chemotherapy (FUC), the predictive value of TS for response and survival in this setting is unclear. This meta-analysis aimed to estimate prognostic and predictive significance of TS more precisely

[1]  J. Marin,et al.  Mechanisms of Resistance to Chemotherapy in Gastric Cancer. , 2016, Anti-cancer agents in medicinal chemistry.

[2]  S. Bhatia,et al.  Impact of care at comprehensive cancer centers on outcome: Results from a population‐based study , 2015, Cancer.

[3]  H. Mamon,et al.  Optimal management of resectable gastric adenocarcinoma , 2015, Expert review of anticancer therapy.

[4]  Xiaoping Zhou,et al.  Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer , 2014, World Journal of Surgical Oncology.

[5]  Jianqing Sun,et al.  Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy , 2014, Tumor Biology.

[6]  H. Imamura,et al.  Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer , 2014, Gastric Cancer.

[7]  Renzo Boldorini,et al.  ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.

[8]  Ying-chao Wang,et al.  An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens , 2013, Molecular Biology Reports.

[9]  L. Shen,et al.  Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin , 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  H. Lee,et al.  Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes , 2011, Medical oncology.

[11]  J. Roh,et al.  Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer , 2011, Anti-cancer drugs.

[12]  Hyuk-Chan Kwon,et al.  Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[13]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[14]  T. Hwang,et al.  Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy , 2010, Langenbeck's Archives of Surgery.

[15]  M. Azuma,et al.  Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy , 2009, Pharmacogenetics and genomics.

[16]  Tianshu Liu,et al.  Polymorphism of thymidylate synthase gene and chemosensitivity of 5‐fluorouracil regimen in metastatic gastrointestinal cancer , 2009, Journal of digestive diseases.

[17]  S. Im,et al.  Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival , 2009, British Journal of Cancer.

[18]  R. Haba,et al.  The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer. , 2008, Hepato-Gastroenterology.

[19]  R. Rosell,et al.  ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen , 2008, British Journal of Cancer.

[20]  Y. Shimada,et al.  Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer , 2008, British Journal of Cancer.

[21]  Joon-Oh Park,et al.  Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy , 2008, Clinical Cancer Research.

[22]  D. Hua,et al.  Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouraci-based adjuvant chemotherapy for gastric cancer , 2007 .

[23]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[24]  M. Roh,et al.  Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Shimizu,et al.  Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer , 2004, British Journal of Cancer.

[26]  B. Mellado,et al.  Low Thymidylate Synthase Expression in the Primary Tumor Predicts Favorable Clinical Outcome in Resected Gastric Cancer Patients Treated with Adjuvant Tegafur , 2004, Oncology.

[27]  J. Little,et al.  Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. , 2004, American journal of epidemiology.

[28]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[29]  R. James,et al.  Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials. , 2002, European journal of cancer.

[30]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[31]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[32]  M. Fukushima,et al.  Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. , 2000, International journal of oncology.

[33]  Yoichi Tanaka,et al.  Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer , 1999, Gastric Cancer.

[34]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[35]  Po-Huang Lee,et al.  High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5‐fluorouracil‐based systemic chemotherapy , 1998, Cancer.

[36]  E. Van Cutsem,et al.  Reporting on the results of cancer treatment in patients with metastatic liver disease: proposal of symmetric size-dependent CT-criteria for response. , 1996, Annals of Oncology.

[37]  J. Kleeff,et al.  Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry , 2015, Gastric Cancer.

[38]  M. Zhong,et al.  Predictive value of thymidylate synthase expression in gastric cancer: a systematic review with meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[39]  S. Kang,et al.  Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy , 2010, Digestive Diseases and Sciences.

[40]  M. Cho,et al.  A High Thymidylate Synthase Expression is Related to Better Outcome for Advanced Gastric Cancer Patients Treated with 5-FU Chemotherapy after Curative Resection , 2006 .

[41]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.